# Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

> **NCT03787290** · PHASE2 · SUSPENDED · sponsor: **Massachusetts General Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo
- **DEVICE:** Whole-Body Hyperthermia

## Key facts

- **NCT ID:** NCT03787290
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 35 (ESTIMATED)
- **Why stopped:** we were not able to get the study drug due to covid
- **Last updated:** 2025-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787290, "Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03787290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*